RetinalGenix Technologies Inc. financial data

Symbol
RTGN on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
1450 North Mcdowell Boulevard, Suite 150, Petaluma, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -101 % -0.64%
Return On Equity 258 % -31.5%
Return On Assets -28.1K % +79.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.8M shares +2.97%
Common Stock, Shares, Outstanding 17.9M shares +3.41%
Entity Public Float 15.5M USD +13.5%
Common Stock, Value, Issued 1.79K USD +0.17%
Weighted Average Number of Shares Outstanding, Basic 17.7M shares +2.32%
Weighted Average Number of Shares Outstanding, Diluted 17.7M shares +2.32%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 153K USD +12.7%
General and Administrative Expense 1.02M USD +20.6%
Costs and Expenses 79.3K USD +16.5%
Net Income (Loss) Attributable to Parent -3.73M USD +7.98%
Earnings Per Share, Basic -0.21 USD/shares +16%
Earnings Per Share, Diluted -0.21 USD/shares -300%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44 USD -98.8%
Assets, Current 50.4K USD +575%
Property, Plant and Equipment, Net 131 USD -43.3%
Assets 50.5K USD +556%
Accounts Payable, Current 340K USD
Liabilities 1.57M USD +4.01%
Retained Earnings (Accumulated Deficit) -13.3M USD -39.1%
Stockholders' Equity Attributable to Parent -1.52M USD -1.18%
Liabilities and Equity 50.5K USD +556%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -143K USD -84.2%
Net Cash Provided by (Used in) Financing Activities 193K USD +127%
Common Stock, Shares Authorized 80M shares 0%
Common Stock, Shares, Issued 17.9M shares +3.41%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.4K USD +578%
Depreciation 25 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 1.65M USD +20.3%
Preferred Stock, Shares Authorized 40M shares 0%
Additional Paid in Capital 11.7M USD +46.2%
Deferred Tax Assets, Net of Valuation Allowance 3.32M USD +23.3%
Interest Expense 3.84K USD -17.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%